Adour Adrouny, MD
Internal Medicine · Chico
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Enloe Specialty Physicians Inc · Sutter Coast Hospital
Looking this up.
Hospitals listed: Adventist Health Clearlake · Enloe Health · Orchard Hospital · Oroville Hospital · Sutter Coast Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Adrouny’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A34013 · Current
Licensed to practise in California · since 1979 · expires 2027-05-31 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health ClearlakeClearlake, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 4 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
- Enloe HealthChico, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Enloe Medical CenterPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.9 (5.5 to 8.6) · 730 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.185, Oct 2024 – Sep 2025
- Orchard HospitalGridley, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency department74% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Oroville HospitalOroville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of OroHealth CorporationPatients rate it 1 of 5 · 35% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Postoperative respiratory failure rate: 16.04 (9.53 to 22.55) · 404 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (11.1 to 19.4) · 136 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.262, Oct 2024 – Sep 2025
- Sutter Coast HospitalCrescent City, CAAcute Care Hospital · Government - Hospital District or Authority · No emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 65% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Adventist Health Clearlake
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 8.5 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.6 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.7 · 52 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 358 cases | None | Jul 2024 – Jun 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.497 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.7 · 79 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -34.6 · 78 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 0.7 · 130 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 127 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19) · 488 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 35 cases | No different | Jan 2024 – Dec 2024 |
What patients said (179 patients answered, 19% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 5 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 84% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 91% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 73% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for Enloe Health
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.9 (5.5 to 8.6) · 730 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.185 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.79 (0.96 to 2.62) · 2,849 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.74 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.04 (164.55 to 241.54) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 117 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.8 · 377 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.4 · 377 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 1,088 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 1,160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.2 · 375 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 4,102 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 14,875 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.17 (0 to 0.34) · 15,303 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.75 (2.11 to 5.39) · 3,517 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.14 (0.71 to 3.56) · 1,262 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.89 (1.62 to 4.17) · 3,062 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.91 (1.48 to 12.34) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.66 to 7.91) · 1,219 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.04 (0.64 to 3.43) · 643 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.71 (0.24 to 1.18) · 11,884 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 150 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.739 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.481 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.381 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.344 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 328 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.7 · 1,020 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.9 · 400 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9.3 · 1,292 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.3 · 1,204 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 1,055 cases | None | Jul 2023 – Jun 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.4 (10.4 to 14.7) · 730 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 102 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 90 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 304 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.9 (12.1 to 18.1) · 3,626 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 1,340 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,476 patients answered, 21% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 57% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Orchard Hospital
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for pneumonia patientsComplications and deaths | 18.2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 80 cases | None | Jul 2024 – Jun 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 63.4 · 44 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 25 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.5) · 48 cases | No different | Jan 2022 – Dec 2024 |
| Room was "always" clean | 87% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 89% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
See every measure and the patient survey for Oroville Hospital
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 4 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative respiratory failure rateComplications and deaths | 16.04 (9.53 to 22.55) · 404 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (11.1 to 19.4) · 136 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.07 (0.1 to 2.04) · 1,061 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.94 (0.64 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.51 (102.1 to 220.92) · 64 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 5.3 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.6 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.6 · 205 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 749 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 19.1 · 141 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 1,984 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.33) · 7,583 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.12 to 0.5) · 7,702 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.75 (0.69 to 4.81) · 1,113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.44 (0 to 3.05) · 384 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.71 (0.23 to 3.2) · 1,061 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.47 (1.06 to 7.88) · 340 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 214 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.11 (0 to 0.69) · 4,910 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.497 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.451 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 39 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 26.7 · 239 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -24 · 54 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 66.7 · 254 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 60.8 · 898 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 25.5 · 851 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.4 (2.9 to 6.6) · 136 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.8 · 176 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 22.8 · 96 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 17.9) · 1,050 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 285 cases | No different | Jan 2024 – Dec 2024 |
What patients said (769 patients answered, 12% of those asked)
| Cleanliness | 1 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 1 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 43% |
| Nurses "always" communicated well | 64% |
| Doctors "always" communicated well | 66% |
| Staff "always" explained | 45% |
| Yes, staff "did" give patients this information | 77% |
| Yes, staff "did" give patients information about help after discharge | 74% |
| Doctors "always" explained things so they could understand | 60% |
| Doctors "always" listened carefully | 63% |
| Doctors "always" treated them with courtesy and respect | 75% |
| Patients who gave a rating of "9" or "10" (high) | 35% |
| Staff "always" explained new medications | 57% |
| Nurses "always" explained things so they could understand | 59% |
| Nurses "always" listened carefully | 60% |
| Nurses "always" treated them with courtesy and respect | 73% |
| "Always" quiet at night | 29% |
| "YES", patients would definitely recommend the hospital | 35% |
| Staff "always" explained possible side effects | 33% |
| Yes, staff "did" give patients information about possible symptoms | 80% |
See every measure and the patient survey for Sutter Coast Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 1 worse of 5 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0 to 2.02) · 178 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.95 (0.5 to 1.39) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 15.8 · 108 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 43 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 416 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,503 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,449 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.27 (1.84 to 6.7) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.21 (0.52 to 3.91) · 263 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.33 (0 to 17.93) · 59 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.01 (1.73 to 10.29) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 74 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0 to 1.43) · 1,201 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 82 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 14.1 · 109 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.4 · 169 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 114 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.3 (4.1 to 9.3) · 79 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.7 (7.4 to 14.9) · 79 cases | No different | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.2 to 17.8) · 499 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.7) · 62 cases | No different | Jan 2024 – Dec 2024 |
What patients said (283 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 4 |
| Recommend hospital | 3 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 59% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$134,086
Medicare paid this office $134,086 for 600 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 451 | $85,494 | $81 |
| Long return visit (40+ min) | 89 | $13,123 | $113 |
| New patient visit (60+ min) | 80 | $12,879 | $161 |
| New patient visit (45+ min) | 51 | $4,800 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $4,203 | $131 |
See all 8 services
| Return visit (30+ min) | 451 | $85,494 | $81 |
| Long return visit (40+ min) | 89 | $13,123 | $113 |
| New patient visit (60+ min) | 80 | $12,879 | $161 |
| New patient visit (45+ min) | 51 | $4,800 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $4,203 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,138 | $62 |
| Short return visit (20+ min) | 47 | $3,222 | $56 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,656 | $97 |
Who their Medicare patients are
600 Original Medicare patients in 2024. Average age 74 · Under 65 11% · 85 and older 12% · Women 51% · Also on Medicaid 33% · Health risk score 1.93. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Cancer 41% · Diabetes 33% · Chronic kidney disease 29% · COPD 29% · Coronary heart disease 24% · Heart failure 22% · Atrial fibrillation 22% · Depression 22% · Dementia 10% · Stroke 10%.
The office billed $457,154, Medicare allowed $183,832 and paid $134,086; for 1,555 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 600 | 1,555 | 74 | 1.93 | $457,154 | $134,086 |
| 2023 | 498 | 1,127 | 74 | 1.63 | $309,671 | $90,646 |
| 2022 | 426 | 1,150 | 74 | 1.61 | $350,595 | $85,306 |
| 2021 | 409 | 1,318 | 74 | 1.77 | $285,489 | $83,906 |
| 2020 | 391 | 10,397 | 73 | 1.95 | $687,940 | $126,266 |
| 2019 | 373 | 33,137 | 74 | 1.99 | $1,350,430 | $215,355 |
| 2018 | 599 | 28,800 | 74 | 2.14 | $1,543,103 | $222,739 |
| 2017 | 688 | 12,621 | 75 | 1.88 | $863,745 | $189,865 |
| 2016 | 544 | 37,341 | 75 | 1.35 | $1,087,072 | $546,529 |
| 2015 | 707 | 26,180 | 74 | 1.31 | $1,452,576 | $646,144 |
| 2014 | 663 | 24,066 | 75 | 1.27 | $1,817,720 | $673,214 |
| 2013 | 786 | 52,611 | 74 | 1.19 | $2,682,351 | $1,087,618 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 395 | $62,693 | $79 |
| New patient visit (45+ min) | 127 | $14,293 | $113 |
| Long return visit (40+ min) | 37 | $4,984 | $125 |
| Short return visit (20+ min) | 31 | $1,650 | $53 |
2022: 8 services
| Return visit (30+ min) | 224 | $29,934 | $82 |
| Short return visit (20+ min) | 224 | $25,776 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $6,798 | $83 |
| New patient visit (30+ min) | 87 | $6,107 | $70 |
| New patient visit (45+ min) | 46 | $5,113 | $111 |
| Hospital discharge day management, more than 30 minutes | 22 | $1,969 | $86 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 14 | $1,900 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,826 | $140 |
2021: 12 services
| Short return visit (20+ min) | 286 | $42,002 | $64 |
| Return visit (30+ min) | 111 | $14,079 | $83 |
| New patient visit (30+ min) | 117 | $9,006 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,813 | $80 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 20 | $2,797 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,118 | $163 |
| New patient visit (45+ min) | 13 | $1,610 | $124 |
| Long return visit (40+ min) | 11 | $1,446 | $131 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $835 | $70 |
| Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; second dose | 24 | $694 | $29 |
| Short return visit | 19 | $686 | $34 |
| Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; first dose | 14 | $294 | $18 |
2020: 13 services
| Short return visit (20+ min) | 258 | $39,213 | $50 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12 | $22,597 | None |
| Return visit (30+ min) | 68 | $5,656 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $5,052 | $87 |
| New patient visit (30+ min) | 66 | $5,022 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,246 | $148 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 19 | $2,664 | $140 |
| Long return visit (40+ min) | 20 | $1,943 | $97 |
| New patient visit (45+ min) | 16 | $1,833 | $115 |
| New patient visit (15+ min) | 35 | $1,577 | $45 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,532 | $90 |
| Injection of drug or substance under skin or into muscle | 24 | $581 | $11 |
| Short return visit | 15 | $497 | $33 |
2019: 12 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $72,909 | None |
| Short return visit (20+ min) | 198 | $24,292 | $51 |
| Return visit (30+ min) | 131 | $17,454 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $7,249 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $5,616 | $83 |
| New patient visit (45+ min) | 28 | $3,547 | $127 |
| New patient visit (30+ min) | 41 | $3,077 | $75 |
| Long return visit (40+ min) | 24 | $2,715 | $113 |
| Injection of drug or substance under skin or into muscle | 39 | $2,608 | $13 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $1,953 | $140 |
| Short return visit | 43 | $1,571 | $32 |
| New patient visit (15+ min) | 23 | $1,123 | $49 |
2018: 14 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $48,111 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 256 | $45,902 | $168 |
| Short return visit (20+ min) | 174 | $19,500 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $7,365 | $82 |
| Return visit (30+ min) | 61 | $5,866 | $72 |
| Initial hospital observation care per day, typically 70 minutes | 35 | $5,507 | $157 |
| New patient visit (30+ min) | 70 | $4,753 | $68 |
| Advance care planning, first 30 minutes | 44 | $2,819 | $64 |
| Short return visit | 73 | $2,624 | $28 |
| Injection of drug or substance under skin or into muscle | 31 | $2,610 | $16 |
| Hospital discharge day management, more than 30 minutes | 28 | $2,370 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,817 | $57 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $1,570 | $121 |
| New patient visit (15+ min) | 23 | $1,101 | $48 |
2017: 13 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 171 | $28,994 | $167 |
| Return visit (30+ min) | 183 | $19,115 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 142 | $17,127 | $85 |
| Short return visit (20+ min) | 131 | $16,479 | $53 |
| New patient visit (30+ min) | 104 | $6,724 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $5,283 | $57 |
| Hospital discharge day management, more than 30 minutes | 41 | $3,569 | $87 |
| Initial hospital observation care per day, typically 70 minutes | 12 | $1,841 | $153 |
| Long return visit (40+ min) | 14 | $1,194 | $85 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $1,167 | $69 |
| Injection of drug or substance under skin or into muscle | 14 | $1,049 | $21 |
| New patient visit (45+ min) | 11 | $1,049 | $95 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $518 | $15 |
2016: 25 services
| Return visit (30+ min) | 294 | $66,041 | $88 |
| New patient visit (45+ min) | 158 | $18,671 | $118 |
| Short return visit (20+ min) | 106 | $18,443 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 15 | $18,148 | $135 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $9,204 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,336 | $87 |
| New patient visit (60+ min) | 32 | $5,775 | $180 |
| Long return visit (40+ min) | 36 | $4,326 | $117 |
| New patient visit (30+ min) | 53 | $3,695 | $70 |
| Injection, zoledronic acid, 1 mg | 15 | $2,291 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $1,815 | $17 |
| Short return visit | 17 | $1,344 | $38 |
| Injection of drug or substance under skin or into muscle | 21 | $1,324 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $981 | $20 |
| Administration of influenza virus vaccine | 21 | $665 | $32 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 22 | $348 | $16 |
| Inhalation treatment for airway obstruction or sputum production | 18 | $335 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 14 | $190 | $14 |
| Urinalysis, manual test | 39 | $160 | $3 |
| 5% dextrose/water (500 ml = 1 unit) | 17 | $115 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $65 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 24 | $59 | None |
| Infusion, normal saline solution, 250 cc | 17 | $34 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 14 | $22 | None |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 15 | $1 | None |
2015: 28 services
| Return visit (30+ min) | 373 | $87,259 | $96 |
| New patient visit (45+ min) | 202 | $25,820 | $128 |
| Short return visit (20+ min) | 153 | $19,681 | $65 |
| Administration of chemotherapy into vein, 1 hour or less | 22 | $16,512 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $14,805 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $13,454 | $71 |
| New patient visit (60+ min) | 49 | $8,691 | $177 |
| New patient visit (30+ min) | 85 | $7,534 | $89 |
| Long return visit (40+ min) | 53 | $7,192 | $128 |
| Injection, zoledronic acid, 1 mg | 17 | $6,030 | None |
| Short return visit | 37 | $2,901 | $40 |
| Injection of drug or substance under skin or into muscle | 50 | $2,779 | $25 |
| Administration of chemotherapy into vein, each additional hour | 16 | $2,061 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $1,593 | $18 |
| Administration of influenza virus vaccine | 26 | $827 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $747 | $18 |
| Inhalation treatment for airway obstruction or sputum production | 34 | $732 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $695 | $20 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 30 | $465 | $16 |
| Blood test, clotting time | 14 | $440 | $5 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 17 | $245 | $14 |
| Urinalysis, manual test | 45 | $174 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $106 | None |
| 5% dextrose/water (500 ml = 1 unit) | 20 | $76 | None |
| Injection, ceftriaxone sodium, per 250 mg | 11 | $18 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $17 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $14 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 16 | $2 | None |
2014: 40 services
| Return visit (30+ min) | 346 | $79,758 | $91 |
| New patient visit (45+ min) | 197 | $26,723 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $23,290 | $92 |
| Insertion of needle or tube into artery of arm or leg | 32 | $22,137 | $152 |
| Administration of chemotherapy into vein, 1 hour or less | 24 | $19,960 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 45 | $15,351 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $12,412 | $177 |
| Short return visit (20+ min) | 132 | $12,187 | $60 |
| New patient visit (60+ min) | 56 | $10,005 | $179 |
| Injection, zoledronic acid, 1 mg | 12 | $8,867 | None |
| Short return visit | 70 | $5,852 | $40 |
| Long return visit (40+ min) | 40 | $5,041 | $126 |
| New patient visit (30+ min) | 58 | $4,502 | $78 |
| Injection of drug or substance under skin or into muscle | 73 | $4,398 | $24 |
| Administration of chemotherapy into vein, each additional hour | 20 | $3,305 | $28 |
| Injection of drug or substance into vein | 18 | $3,142 | $57 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 30 | $2,600 | $18 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,598 | $30 |
| Simple repair of surface wound of scalp, neck, underarms, trunk, arms, or legs, 2.5 cm or less | 13 | $1,087 | $78 |
| Blood test, clotting time | 22 | $873 | $5 |
| Irrigation of implanted venous access drug delivery device | 17 | $790 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $740 | $18 |
| Inhalation treatment for airway obstruction or sputum production | 28 | $569 | $19 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 35 | $527 | $15 |
| Administration of influenza virus vaccine | 11 | $342 | $31 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 16 | $256 | $16 |
| 5% dextrose/water (500 ml = 1 unit) | 39 | $232 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 20 | $228 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 27 | $121 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 20 | $95 | None |
| Urinalysis, manual test | 17 | $62 | $3 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 12 | $61 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $58 | None |
| Infusion, normal saline solution , 1000 cc | 11 | $57 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 27 | $43 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 17 | $36 | None |
| Injection, ceftriaxone sodium, per 250 mg | 17 | $31 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $24 | None |
| Infusion, normal saline solution, 250 cc | 24 | $18 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 18 | $4 | None |
2013: 44 services
| Return visit (30+ min) | 325 | $80,268 | $94 |
| New patient visit (45+ min) | 336 | $44,584 | $133 |
| Administration of chemotherapy into vein, 1 hour or less | 28 | $36,516 | $147 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 51 | $27,517 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $27,090 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $24,376 | $172 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $21,349 | None |
| Insertion of needle and/or catheter for dialysis | 35 | $20,150 | $135 |
| Injection, zoledronic acid (zometa), 1 mg | 11 | $16,824 | None |
| Insertion of needle or tube into artery of arm or leg | 22 | $15,359 | $160 |
| Short return visit (20+ min) | 115 | $12,537 | $65 |
| New patient visit (60+ min) | 53 | $9,395 | $177 |
| New patient visit (30+ min) | 78 | $6,887 | $88 |
| Injection of drug or substance under skin or into muscle | 80 | $6,843 | $25 |
| Administration of chemotherapy into vein, each additional hour | 20 | $6,590 | $31 |
| Insertion of artery tube for prolonged infusion | 16 | $5,668 | $113 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $3,045 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 19 | $2,947 | $18 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,580 | $32 |
| Long return visit (40+ min) | 17 | $2,268 | $119 |
| Administration of influenza virus vaccine | 64 | $2,090 | $32 |
| Injection of drug or substance into vein | 12 | $2,051 | $59 |
| Short return visit | 35 | $1,925 | $42 |
| Blood test, clotting time | 22 | $1,089 | $5 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 27 | $1,086 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,026 | $21 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 65 | $944 | $14 |
| Removal of impacted ear wax | 16 | $693 | $39 |
| Inhalation treatment for airway obstruction or sputum production | 25 | $546 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | $408 | $18 |
| 5% dextrose/water (500 ml = 1 unit) | 43 | $352 | None |
| Urinalysis, manual test | 88 | $343 | $3 |
| Administration of vaccine | 13 | $307 | $24 |
| 5% dextrose/normal saline (500 ml = 1 unit) | 29 | $273 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 23 | $175 | None |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 13 | $163 | $13 |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $110 | None |
| Infusion, normal saline solution , 1000 cc | 21 | $95 | None |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $36 | None |
| Infusion, normal saline solution, 250 cc | 31 | $31 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 23 | $30 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $25 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 24 | $6 | None |
| Injection, ketorolac tromethamine, per 15 mg | 12 | $5 | None |
Medicaid work
$16,685 in 2024
Medicaid paid $16,685 for 437 billed services this clinician did in 2024, up to 32 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 408 | $13,850 |
| New patient visit (60+ min) | 29 | $2,835 |
| 2024 | 437 | 2 | 32 | $16,685 |
| 2023 | 310 | 2 | 40 | $12,302 |
| 2022 | 293 | 2 | 29 | $7,910 |
| 2021 | 228 | 2 | 31 | $3,709 |
| 2020 | 285 | 2 | 29 | $6,004 |
| 2019 | 60 | 2 | 19 | $1,177 |
| 2018 | 25 | 1 | 13 | $2,403 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 296 | $11,331 |
| New patient visit (45+ min) | 14 | $971 |
2022
| Short return visit (20+ min) | 194 | $4,327 |
| Return visit (30+ min) | 99 | $3,583 |
2021
| Short return visit (20+ min) | 214 | $3,501 |
| Return visit (30+ min) | 14 | $208 |
2020
| Short return visit (20+ min) | 273 | $5,224 |
| Return visit (30+ min) | 12 | $780 |
2019
| Short return visit (20+ min) | 38 | $622 |
| Return visit (30+ min) | 22 | $555 |
2018
| 1ST HOSP IP/OBS HIGH 75 | 25 | $2,403 |
Drugs they prescribed that Part D paid
$2,746,608
Pharmacies billed $2,746,608 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (50 of 972) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%. Long-acting opioids: 24% of their opioid prescriptions.
744 generic and fewer than 11 brand-name prescriptions · $2,746,608 in drug cost · 39 antibiotic prescriptions to 18 people · 12 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Imbruvica | None | 25 | $402,415 | $16,097 |
| Tagrisso | None | 18 | $301,496 | $16,750 |
| Hizentra | Immune globulin | 13 | $279,267 | $21,482 |
| Calquence | None | 24 | $277,695 | $11,571 |
| Xtandi | None | 18 | $241,850 | $13,436 |
See all 30 drugs
| Imbruvica | None | 25 | $402,415 | $16,097 |
| Tagrisso | None | 18 | $301,496 | $16,750 |
| Hizentra | Immune globulin | 13 | $279,267 | $21,482 |
| Calquence | None | 24 | $277,695 | $11,571 |
| Xtandi | None | 18 | $241,850 | $13,436 |
| Jakafi | None | 14 | $241,577 | $17,256 |
| Abiraterone Acetate | None | 42 | $204,518 | $4,869 |
| Revlimid | None | 11 | $174,125 | $15,830 |
| Lenalidomide | None | 12 | $170,329 | $14,194 |
| Brukinsa | None | 15 | $127,879 | $8,525 |
| Sprycel | None | 12 | $63,780 | $5,315 |
| Eliquis | None | 31 | $34,240 | $1,105 |
| Xarelto | None | 21 | $15,003 | $714 |
| Dexamethasone | None | 54 | $1,445 | $27 |
| Bicalutamide | None | 27 | $952 | $35 |
| Anastrozole | None | 40 | $774 | $19 |
| Hydroxyurea | None | 22 | $617 | $28 |
| Prochlorperazine Maleate | None | 65 | $577 | $9 |
| Ondansetron | None | 73 | $557 | $8 |
| Acyclovir | None | 36 | $523 | $15 |
| Exemestane | None | 13 | $463 | $36 |
| Tamoxifen Citrate | None | 15 | $441 | $29 |
| Prednisone | None | 38 | $381 | $10 |
| Letrozole | None | 11 | $308 | $28 |
| Hydrocodone-Acetaminophen | None | 22 | $292 | $13 |
| Warfarin | None | 27 | $211 | $8 |
| Gabapentin | None | 22 | $159 | $7 |
| Sulfamethoxazole-Trimethoprim | None | 31 | $155 | $5 |
| Olanzapine | None | 12 | $148 | $12 |
| Alendronate | None | 12 | $111 | $9 |
Year by year
| 2024 | 972 | 180 | 5% (50) | None | $2,746,608 |
| 2023 | 860 | 165 | 5% (45) | 21% | $2,647,878 |
| 2022 | 832 | 145 | 8% (62) | 16% | $1,739,158 |
| 2021 | 740 | 126 | 12% (89) | 15% | $1,342,642 |
| 2020 | 677 | 121 | 11% (72) | 23% | $1,388,660 |
| 2019 | 347 | 73 | 6% (19) | 29% | $1,046,641 |
| 2018 | 373 | 87 | 4% (14) | 25% | $905,879 |
| 2017 | 793 | 195 | 4% (35) | 18% | $625,957 |
| 2016 | 1,089 | 156 | 4% (44) | 19% | $586,321 |
| 2015 | 1,231 | 214 | 5% (65) | None | $439,147 |
| 2014 | 1,049 | 168 | 4% (43) | None | $343,441 |
| 2013 | 935 | 131 | 4% (37) | 27% | $494,681 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Tagrisso | 24 | $388,030 | $16,168 |
| Imbruvica | 21 | $381,638 | $18,173 |
| Abiraterone Acetate | 41 | $357,444 | $8,718 |
| Lenalidomide | 19 | $251,011 | $13,211 |
| Lynparza | 11 | $178,416 | $16,220 |
| Calquence | 14 | $143,997 | $10,286 |
| Sprycel | 15 | $85,937 | $5,729 |
| Eliquis | 30 | $19,086 | $636 |
| Xarelto | 16 | $12,043 | $753 |
| Exemestane | 21 | $4,355 | $207 |
| Anagrelide | 11 | $2,093 | $190 |
| Anastrozole | 30 | $1,766 | $59 |
| Dexamethasone | 59 | $1,626 | $28 |
| Tamoxifen Citrate | 40 | $1,169 | $29 |
| Bicalutamide | 18 | $1,005 | $56 |
| Hydroxyurea | 24 | $888 | $37 |
| Ondansetron | 44 | $629 | $14 |
| Prochlorperazine Maleate | 48 | $581 | $12 |
| Hydrocodone-Acetaminophen | 29 | $526 | $18 |
| Tamsulosin | 12 | $455 | $38 |
| Prednisone | 51 | $382 | $7 |
| Gabapentin | 19 | $329 | $17 |
| Diphenoxylate-Atropine | 11 | $276 | $25 |
| Potassium Chloride | 11 | $237 | $22 |
| Levothyroxine | 12 | $133 | $11 |
| Warfarin | 21 | $122 | $6 |
2022: 22 drugs
| Imbruvica | 36 | $647,000 | $17,972 |
| Abiraterone Acetate | 34 | $282,759 | $8,316 |
| Tagrisso | 13 | $204,204 | $15,708 |
| Revlimid | 12 | $148,583 | $12,382 |
| Sprycel | 14 | $134,017 | $9,573 |
| Eliquis | 18 | $10,556 | $586 |
| Xarelto | 13 | $7,794 | $600 |
| Dexamethasone | 53 | $1,729 | $33 |
| Anastrozole | 38 | $1,578 | $42 |
| Tamoxifen Citrate | 53 | $1,284 | $24 |
| Bicalutamide | 31 | $1,132 | $37 |
| Hydroxyurea | 26 | $1,127 | $43 |
| Ondansetron | 39 | $828 | $21 |
| Hydrocodone-Acetaminophen | 33 | $703 | $21 |
| Gabapentin | 23 | $667 | $29 |
| Prednisone | 59 | $536 | $9 |
| Prochlorperazine Maleate | 42 | $534 | $13 |
| Acyclovir | 22 | $492 | $22 |
| Tamsulosin | 18 | $469 | $26 |
| Potassium Chloride | 18 | $345 | $19 |
| Warfarin | 20 | $148 | $7 |
| Allopurinol | 17 | $138 | $8 |
2021: 25 drugs
| Imbruvica | 36 | $509,884 | $14,163 |
| Jakafi | 13 | $277,561 | $21,351 |
| Revlimid | 15 | $207,161 | $13,811 |
| Sprycel | 13 | $178,600 | $13,738 |
| Abiraterone Acetate | 15 | $112,793 | $7,520 |
| Eliquis | 14 | $10,204 | $729 |
| Exemestane | 14 | $2,067 | $148 |
| Hydroxyurea | 32 | $2,031 | $63 |
| Dexamethasone | 42 | $1,602 | $38 |
| Fentanyl | 18 | $1,570 | $87 |
| Megestrol Acetate | 16 | $1,261 | $79 |
| Tamoxifen Citrate | 52 | $1,243 | $24 |
| Anastrozole | 35 | $833 | $24 |
| Bicalutamide | 14 | $686 | $49 |
| Ondansetron | 44 | $670 | $15 |
| Hydrocodone-Acetaminophen | 44 | $630 | $14 |
| Prochlorperazine Maleate | 39 | $491 | $13 |
| Prednisone | 38 | $380 | $10 |
| Gabapentin | 11 | $322 | $29 |
| Tamsulosin | 16 | $312 | $19 |
| Acyclovir | 12 | $252 | $21 |
| Allopurinol | 11 | $126 | $11 |
| Escitalopram | 14 | $120 | $9 |
| Hydromorphone | 12 | $113 | $9 |
| Warfarin | 17 | $109 | $6 |
2020: 15 drugs
| Revlimid | 34 | $376,750 | $11,081 |
| Imbruvica | 24 | $288,649 | $12,027 |
| Zytiga | 13 | $139,374 | $10,721 |
| Xarelto | 11 | $5,430 | $494 |
| Fentanyl | 22 | $2,168 | $99 |
| Dexamethasone | 47 | $1,661 | $35 |
| Tamoxifen Citrate | 36 | $1,437 | $40 |
| Hydroxyurea | 29 | $1,323 | $46 |
| Megestrol Acetate | 15 | $1,104 | $74 |
| Ondansetron | 69 | $970 | $14 |
| Anastrozole | 48 | $955 | $20 |
| Hydrocodone-Acetaminophen | 18 | $275 | $15 |
| Prednisone | 30 | $271 | $9 |
| Prochlorperazine Maleate | 20 | $246 | $12 |
| Warfarin | 15 | $88 | $6 |
2019: 11 drugs
| Ibrance | 18 | $217,323 | $12,073 |
| Imbruvica | 15 | $196,785 | $13,119 |
| Jakafi | 16 | $172,413 | $10,776 |
| Hydroxyurea | 13 | $811 | $62 |
| Tamoxifen Citrate | 19 | $733 | $39 |
| Anastrozole | 22 | $572 | $26 |
| Bicalutamide | 12 | $371 | $31 |
| Dexamethasone | 16 | $341 | $21 |
| Ondansetron | 23 | $187 | $8 |
| Prednisone | 23 | $157 | $7 |
| Warfarin | 17 | $131 | $8 |
2018: 8 drugs
| Jakafi | 35 | $386,350 | $11,039 |
| Imbruvica | 13 | $129,757 | $9,981 |
| Tamoxifen Citrate | 32 | $1,335 | $42 |
| Hydroxyurea | 17 | $774 | $46 |
| Anastrozole | 27 | $538 | $20 |
| Prednisone | 29 | $332 | $11 |
| Ondansetron | 21 | $205 | $10 |
| Ondansetron Odt | 20 | $129 | $6 |
2017: 20 drugs
| Revlimid | 20 | $253,717 | $12,686 |
| Imbruvica | 21 | $152,635 | $7,268 |
| Jakafi | 13 | $77,557 | $5,966 |
| Enoxaparin | 12 | $5,596 | $466 |
| Tamoxifen Citrate | 38 | $1,011 | $27 |
| Levothyroxine | 25 | $747 | $30 |
| Anastrozole | 24 | $498 | $21 |
| Hydroxyurea | 16 | $471 | $29 |
| Atorvastatin | 19 | $367 | $19 |
| Prednisone | 21 | $298 | $14 |
| Simvastatin | 22 | $257 | $12 |
| Warfarin | 11 | $247 | $22 |
| Levofloxacin | 12 | $232 | $19 |
| Amlodipine Besylate | 29 | $220 | $8 |
| Azithromycin | 24 | $208 | $9 |
| Atenolol | 16 | $199 | $12 |
| Amoxicillin-Clavulanate Potass | 16 | $153 | $10 |
| Alprazolam | 20 | $131 | $7 |
| Hydrochlorothiazide | 11 | $105 | $10 |
| Ondansetron Odt | 13 | $99 | $8 |
2016: 34 drugs
| Revlimid | 27 | $352,049 | $13,039 |
| Xarelto | 15 | $5,397 | $360 |
| Celecoxib | 14 | $1,295 | $92 |
| Oxycodone-Acetaminophen | 14 | $1,024 | $73 |
| Hydroxyurea | 28 | $1,021 | $36 |
| Levothyroxine | 42 | $1,021 | $24 |
| Atorvastatin | 47 | $1,004 | $21 |
| Anastrozole | 21 | $993 | $47 |
| Duloxetine | 12 | $932 | $78 |
| Warfarin | 51 | $572 | $11 |
| Simvastatin | 32 | $493 | $15 |
| Irbesartan-Hydrochlorothiazide | 12 | $492 | $41 |
| Tamsulosin | 16 | $475 | $30 |
| Amlodipine Besylate | 55 | $405 | $7 |
| Atenolol | 27 | $394 | $15 |
| Allopurinol | 15 | $364 | $24 |
| Metoprolol | 18 | $363 | $20 |
| Tamoxifen Citrate | 11 | $335 | $30 |
| Metformin | 20 | $303 | $15 |
| Hydrocodone-Acetaminophen | 11 | $294 | $27 |
| Omeprazole | 14 | $268 | $19 |
| Amitriptyline | 14 | $218 | $16 |
| Methylprednisolone | 11 | $210 | $19 |
| Alendronate | 18 | $207 | $11 |
| Prednisone | 13 | $195 | $15 |
| Diclofenac | 16 | $168 | $11 |
| Dexamethasone | 13 | $163 | $13 |
| Lisinopril-Hydrochlorothiazide | 13 | $161 | $12 |
| Metoprolol | 20 | $145 | $7 |
| Hydrochlorothiazide | 14 | $127 | $9 |
| Tramadol | 14 | $102 | $7 |
| Azithromycin | 14 | $100 | $7 |
| Ciprofloxacin | 12 | $78 | $6 |
| Labetalol | 12 | $75 | $6 |
2015: 41 drugs
| Jakafi | 12 | $121,457 | $10,121 |
| Imbruvica | 11 | $81,034 | $7,367 |
| Spiriva | 11 | $5,513 | $501 |
| Xarelto | 13 | $5,119 | $394 |
| Zetia | 11 | $4,709 | $428 |
| Benicar Hct | 11 | $2,301 | $209 |
| Celecoxib | 12 | $1,556 | $130 |
| Proair Hfa | 13 | $1,263 | $97 |
| Oxycodone-Acetaminophen | 17 | $1,198 | $70 |
| Atorvastatin | 41 | $998 | $24 |
| Anastrozole | 32 | $883 | $28 |
| Levothyroxine | 33 | $832 | $25 |
| Warfarin | 39 | $639 | $16 |
| Amlodipine Besylate | 55 | $557 | $10 |
| Tamoxifen Citrate | 11 | $513 | $47 |
| Allopurinol | 26 | $470 | $18 |
| Bicalutamide | 26 | $467 | $18 |
| Hydroxyurea | 18 | $463 | $26 |
| Amitriptyline | 15 | $444 | $30 |
| Simvastatin | 42 | $368 | $9 |
| Omeprazole | 24 | $363 | $15 |
| Diclofenac | 17 | $284 | $17 |
| Zolpidem | 12 | $269 | $22 |
| Ondansetron | 14 | $257 | $18 |
| Dexamethasone | 11 | $248 | $23 |
| Hydrocodone-Acetaminophen | 19 | $237 | $12 |
| Atenolol | 22 | $222 | $10 |
| Metformin | 28 | $220 | $8 |
| Amoxicillin-Clavulanate Potass | 13 | $197 | $15 |
| Methylprednisolone | 12 | $188 | $16 |
| Acetaminophen-Codeine | 11 | $157 | $14 |
| Alendronate | 16 | $144 | $9 |
| Azithromycin | 18 | $144 | $8 |
| Metoprolol | 18 | $123 | $7 |
| Labetalol | 12 | $121 | $10 |
| Famotidine | 11 | $105 | $10 |
| Prednisone | 16 | $95 | $6 |
| Ciprofloxacin | 18 | $87 | $5 |
| Lisinopril-Hydrochlorothiazide | 13 | $66 | $5 |
| Hydrochlorothiazide | 13 | $50 | $4 |
| Metformin Hcl Er | 12 | $27 | $2 |
2014: 34 drugs
| Jakafi | 12 | $110,120 | $9,177 |
| Xarelto | 31 | $13,699 | $442 |
| Spiriva | 14 | $6,194 | $442 |
| Combivent Respimat | 14 | $5,749 | $411 |
| Zetia | 13 | $4,006 | $308 |
| Benicar Hct | 12 | $1,996 | $166 |
| Atorvastatin | 47 | $1,400 | $30 |
| Levothyroxine | 31 | $803 | $26 |
| Hydrocodone-Acetaminophen | 28 | $726 | $26 |
| Tamoxifen Citrate | 24 | $718 | $30 |
| Methylprednisolone | 27 | $625 | $23 |
| Warfarin | 33 | $569 | $17 |
| Amlodipine Besylate | 35 | $466 | $13 |
| Diclofenac | 33 | $398 | $12 |
| Simvastatin | 26 | $320 | $12 |
| Fludrocortisone Acetate | 11 | $254 | $23 |
| Atenolol | 23 | $246 | $11 |
| Allopurinol | 30 | $245 | $8 |
| Amox Tr-Potassium Clavulanate | 15 | $222 | $15 |
| Metformin | 11 | $212 | $19 |
| Alendronate | 19 | $204 | $11 |
| Amitriptyline | 20 | $180 | $9 |
| Prednisone | 23 | $161 | $7 |
| Labetalol | 12 | $149 | $12 |
| Ondansetron | 15 | $144 | $10 |
| Dexamethasone | 17 | $114 | $7 |
| Metoprolol | 19 | $111 | $6 |
| Glyburide | 12 | $97 | $8 |
| Zolpidem | 13 | $88 | $7 |
| Hydrochlorothiazide | 17 | $80 | $5 |
| Lisinopril-Hydrochlorothiazide | 13 | $68 | $5 |
| Ciprofloxacin | 12 | $65 | $5 |
| Lisinopril | 17 | $44 | $3 |
| Alprazolam | 12 | $38 | $3 |
2013: 29 drugs
| Revlimid | 20 | $169,424 | $8,471 |
| Femara | 12 | $6,495 | $541 |
| Combivent Respimat | 20 | $5,215 | $261 |
| Xarelto | 11 | $3,040 | $276 |
| Colcrys | 12 | $2,000 | $167 |
| Benicar Hct | 12 | $1,757 | $146 |
| Atorvastatin | 40 | $1,750 | $44 |
| Ondansetron | 33 | $818 | $25 |
| Warfarin | 56 | $764 | $14 |
| Megestrol Acetate | 13 | $574 | $44 |
| Amlodipine Besylate | 35 | $550 | $16 |
| Tamoxifen Citrate | 20 | $532 | $27 |
| Levothyroxine | 24 | $453 | $19 |
| Methylprednisolone | 18 | $448 | $25 |
| Simvastatin | 26 | $397 | $15 |
| Hydrocodone-Acetaminophen | 21 | $387 | $18 |
| Metformin | 14 | $332 | $24 |
| Sertraline | 15 | $239 | $16 |
| Allopurinol | 28 | $196 | $7 |
| Labetalol | 12 | $195 | $16 |
| Atenolol | 15 | $183 | $12 |
| Prednisone | 29 | $170 | $6 |
| Alendronate | 18 | $162 | $9 |
| Metoprolol | 14 | $116 | $8 |
| Lisinopril-Hydrochlorothiazide | 13 | $113 | $9 |
| Prochlorperazine Maleate | 16 | $105 | $7 |
| Hydrochlorothiazide | 14 | $85 | $6 |
| Dexamethasone | 14 | $72 | $5 |
| Lisinopril | 12 | $61 | $5 |
Money from drug and device companies
$458 in 2025
| 2025 | 4 | 4 | None | $458 |
| 2024 | 6 | 10 | None | $786 |
| 2023 | 10 | 12 | None | $457 |
| 2022 | 1 | 2 | None | $63 |
| 2021 | 2 | 2 | None | $55 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Adaptive Biotechnologies | Clonoseq | $126 | 1 payment
|
| Abbvie | Venclexta | $123 | 1 payment
|
| Daiichi Sankyo | Injectafer | $105 | 1 payment
|
| Pfizer | Padcev | $103 | 1 payment
|
See all 4 published payments
| Daiichi Sankyo | Meals · 2025-07-10 | Injectafer | $105 |
| Abbvie | Meals · 2025-06-30 | Venclexta | $123 |
| Adaptive Biotechnologies | Meals · 2025-06-10 | Clonoseq | $126 |
| Pfizer | Meals · 2025-06-03 | Padcev | $103 |
See earlier years (2024, 2023, 2022, 2021)
2024: $786
| AstraZeneca Pharmaceuticals LP | Calquence | $266 | 3 payments
|
| Janssen Biotech | Darzalex | $137 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $132 | 3 payments
|
| Daiichi Sankyo | Injectafer | $102 | 1 payment
|
| Amgen | Kyprolis | $86 | 1 payment
|
| Eisai | Lenvima | $63 | 1 payment
|
2023: $457
| Seagen | Adcetris | $105 | 1 payment
|
| AbbVie | Venclexta | $96 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $71 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $46 | 1 payment
|
| Amgen | Lumakras | $42 | 2 payments
|
| Lilly USA | Cyramza | $24 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $24 | 1 payment
|
| Celgene | Reblozyl | $22 | 1 payment
|
| Alnylam Pharmaceuticals | Oxlumo | $15 | 1 payment
|
| Stemline Therapeutics | Orserdu | $14 | 1 payment
|
2022: $63
| E.R. Squibb & Sons L.L.C. | Opdivo | $63 | 2 payments
|
2021: $55
| Pfizer | Ibrance | $31 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $24 | 1 payment
|
Professional record
- NPI
- 1447298955
- Licence
- CA A34013California A34013: Current · expires 2027-05-31
- Trained
- Tulane University School of Medicine, 1978
- Group
- Enloe Specialty Physicians Inc · Sutter Coast Hospital
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2998 S Bascom Ave, Suite 200, San Jose, CA, 95124
- NPI first listed
- 2006-06-04
- NPI last updated
- 2015-10-15
This is when the NPI record was last certified, not a medical board exam.